Top of this page
Skip navigation, go straight to the content
At UCB,
we aspire to be the patient-preferred biotech leader.
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
The evolving COVID-19 pandemic is profoundly impacting our lives, we all have adapted our ways of living and working.
Techonology allows us to keep in touch. In the last few months, we hosted over 80 virtual meetings.
Do not hesitate to reach out to us – we are here to help!
IR events
| Date | Event details |
|---|---|
| 07 December 2020 | KBC Virtual Roadshow1/1 meetings |
| 11 January 2021 | 39th Annual J.P. Morgan Virtual Healthcare ConferenceUCB will participate from 11-14 January 2021 |
| 25 February 2021 | 2020 full year resultsDetails closer to the date |
Latest News
-
20 Nov 2020
Disposals of own shares
- 17 Nov 2020 UCB’s VIMPAT[®] (lacosamide) CV now approved by FDA in U.S. for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy
- 12 Nov 2020 UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms
2019 integrated report
2020 HY report
Outlook 2020 confirmed
Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges
2020 revenue
€ 5.05 - € 5.15 billion
Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.]
26% - 27%
reflecting the high R&D investment level, including the investment for the Ra Pharma pipeline
Core earnings per share
€ 4.40 - € 4.80
based on an average of 187 million shares outstanding
Contact UCB IR team
investor-relations@ucb.com or a specific team member:
- Antje Witte, VP Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com - Isabelle Ghellynck, Associate Director Investor Relations
Tel: +32 2 559 9588
E-mail: Isabelle.Ghellynck@ucb.com - Nathalie Deldime, Investor Relations Events Manager
Tel: +32 2 559 9291
E-mail: Nathalie.Deldime@ucb.com
UCB IR App
